Introduction. Postoperative pain control is critical in orthopedic surgery. While efficacious analgesics, opiates have rapid tolerance and addictive potential. Metamizole is a non-opioid analgesic primarily inhibiting COX-3, commonly used in Europe and South America, but banned in the U.S. due to concerns about agranulocytosis risk. However, large meta-analyses have not shown significant agranulocytosis when compared to other analgesics. The purpose of this review is to assess the analgesic efficacy of metamizole and potential use in orthopedic surgery. Methods. An electronic review was conducted of PubMed, Web of Science, Cochrane, Embase, and OVID Medline in October 2023. Studies for inclusion were limited to those in which metamizole use was a primary focus, patients were undergoing orthopedic surgery, studies in human patients, and studies reporting in the English language. Results. 1,112 studies were identified and 15 (1.3%) met inclusion criteria. The use of metamizole as a single agent or in combination therapy was described to be superior or non-inferior to alternative analgesics in 10 (66.7%) studies. Metamizole decreased rescue analgesia in 5 (33.3%) articles. No patients experienced agranulocytosis. Conclusions. Metamizole was efficaciously non-inferior to other non-opioid analgesics by demonstrating an opioid sparing effect in over a third of included studies. Metamizole did not have significant differences in incidence or severity of side effects and no cases of agranulocytosis were seen across all studies. These results indicate the potential for metamizole as analgesia in the setting of orthopedic surgery. Future studies should focus on larger cohorts to continue to assess efficacy and risk of agranulocytosis.